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Abstract
Introduction: In this multicenter study on subjective cognitive decline (SCD) in community-
based and memory clinic settings, we assessed the (1) incidence of Alzheimer’s disease (AD) and 
non-AD dementia and (2) determinants of progression to dementia.
Methods: Eleven cohorts provided 2978 participants with SCD and 1391 controls. We estimated 
dementia incidence and identified risk factors using Cox proportional hazards models.
Results: In SCD, incidence of dementia was 17.7 (95% Poisson confidence interval 15.2–20.3)/
1000 person-years (AD: 11.5 [9.6–13.7], non-AD: 6.1 [4.7–7.7]), compared with 14.2 (11.3–17.6) 
in controls (AD: 10.1 [7.7–13.0], non-AD: 4.1 [2.6–6.0]). The risk of dementia was strongly 
increased in SCD in a memory clinic setting but less so in a community-based setting. In addition, 
higher age (hazard ratio 1.1 [95% confidence interval 1.1–1.1]), lower Mini-Mental State 
Examination (0.7 [0.66–0.8]), and apolipoprotein E ε4 (1.8 [1.3–2.5]) increased the risk of 
dementia.
Discussion: SCD can precede both AD and non-AD dementia. Despite their younger age, 
individuals with SCD in a memory clinic setting have a higher risk of dementia than those in 
community-based cohorts.
Keywords
Subjective cognitive decline; Dementia incidence; Preclinical Alzheimer’s disease; Alzheimer’s 
disease; Vascular dementia; Frontotemporal dementia; Dementia Lewy bodies
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1. Introduction
Neurodegenerative changes, eventually leading to dementia due to Alzheimer’s disease 
(AD), begin to accumulate approximately 20 years before clinical symptoms appear [1]. 
With the lack of curative treatment for dementia due to AD, research is moving toward the 
prodromal and preclinical stages of AD [2]. Subjective cognitive decline (SCD) refers to the 
subjective experience of cognitive decline, without objective impairment on cognitive 
assessment [3]. Compared to individuals without SCD, cognitively normal elderly subjects 
experiencing complaints have an increased risk of subsequent objective cognitive decline, 
that is, progression to mild cognitive impairment (MCI) and dementia [4–9]. Therefore, 
SCD has been suggested to be a possible first symptomatic expression of preclinical AD 
[2,3].
The conceptual framework on SCD published by the international Working Group (SCD-I) 
has a focus on SCD as an early harbinger of AD, proposing the SCD-plus criteria as 
potential risk factors for preclinical AD [3]. However, SCD may also precede other dementia 
subtypes with a gradual onset, such as vascular dementia (VaD), dementia with Lewy Bodies 
(DLBs), or frontotemporal dementia (FTD). Although individuals with SCD have an 
increased risk of dementia [4–9], the incidence rate of progression from SCD to AD 
dementia, and especially to non-AD dementia, has not been estimated before.
For cognitively normal individuals, risk factors of dementia include higher age, lower 
education, and apolipoprotein E (APOE) ε4 status [10,11]. Whether these risk factors 
influence the risk of progression to AD and non-AD types of dementia in patients with SCD 
in a similar way remains to be further investigated. The aim of our multicenter study 
including both memory clinic and community-based cohorts of SCD was to estimate 
incidence rates of dementia, both for AD and non-AD.
2. Methods
This collaborative project was initiated during a public meeting of the Subjective Cognitive 
Decline Professional Interest Area during the Alzheimer’s Association International 
Conference in 2015, which was facilitated by the International Society to Advance 
Alzheimer’s Research and Treatment.
2.1. Setting and recruitment
Eleven cohorts provided data, see Table 1 for an overview of participating cohorts and the 
number of subjects included. Across studies, there are differences in operationalization of 
SCD. We deliberately took the case definition of each study as the starting point; Table 1 
provides information on center-specific operationalization of SCD. Cohorts were defined as 
memory clinic setting when patients were referred to the memory clinic by a physician, or 
actively approached the respective center for evaluation. Cohorts were labeled as community 
setting when the study was population based, for example, if recruitment was organized via 
standardized evaluation of eligible participants in a predefined district or when participants 
were recruited by active (media) appeal.
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2.2. Participants
We included SCD participants in the analysis if (1) the participant reported subjective 
experience of cognitive decline on one or more cognitive domains; (2) the participant had 
normal baseline cognition, defined by results of cognitive assessment within normal ranges 
(center-specific), and criteria for MCI or any dementia were not met [12–15], and (3) had at 
least one follow-up assessment (>8 months from baseline) with repeated evaluation of 
diagnosis. Controls were provided by the same cohorts but did not endorse inclusion 
criterion (1). Exclusion criteria were MCI, dementia, alcohol or substance abuse, or any 
psychiatric or neurological disease possibly causing memory complaints (i.e. epilepsy, 
Parkinson’s disease). In sum, 11 cohorts provided 5521 participants; 2978 cases with SCD 
and 1391 controls without SCD, see Fig. 1 for an overview of participant selection.
2.3. Outcome measure
The main outcome measure was progression to dementia. Definitions and criteria of specific 
dementia used in each cohort are provided in the supplement or study design reports. 
Besides dementia due to AD [13,16], we evaluated the following non-AD dementia: VaD 
[17], FTD [14], and DLBs [15]. Other less frequent neurodegenerative causes of dementia, 
such as corticobasal syndrome or progressive supranuclear palsy, were classified as 
“dementia other.”
2.4. Demographic features of the study population
Sociodemographic features and cognition were assessed in each cohort. Here, we report on 
age, sex, education, global cognition, and APOE ε4 carrier status. Information on years of 
education was available for 2142 (71.9%) participants. Cognitive function was screened with 
the Mini-Mental State Examination (MMSE) [18] and available for 2928 (98.3%) 
participants. APOE genotyping was performed according to local procedures and available 
for 2417 (81.2%) participants. We dichotomized APOE ε4 status (0 ε4 alleles vs. 1 or 2 ε4 
alleles).
2.5. Statistical analyses
Data were analyzed using SPSS (version 22; IBM, Armonk, NY, USA) and Stata 15 (Stata 
Statistical Software: Release 15, StataCorp LP). We evaluated baseline characteristics and 
assessed differences between memory clinics and community cohorts using linear mixed 
models (continuous variables) or generalized estimating equations (dichotomous variables), 
taking into account random center effects.
We calculated incidence rates of dementia per 1000 person-years with accompanying 95% 
Poisson confidence intervals and incidence rates of AD and non-AD dementia separately.
We studied the effect of age, sex, MMSE, number of education years, APOE ε4 carrier 
status, and recruitment setting (memory clinic vs. community cohort) on the risk of dementia 
by using shared-frailty Cox proportional hazards models, taking into account within-group 
center effects. We conducted simple and multiple Cox regression models and accounted for 
residual variation in progression risk among studies by including a center-specific random 
effect. To evaluate whether effects of MMSE and education were generalizable between 
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centers, we added mean MMSE and mean number of education years per center as variables. 
Finally, we added interaction effects of recruitment setting and variables age, sex, MMSE, 
and number of education years. We repeated the analyses stratified for AD and non-AD 
dementia.
For visualization, we constructed Kaplan-Meier curves of progression to dementia in general 
and for dementia due to AD and to non-AD per decade of age. When calculating the risk of 
AD, cases progressing to non-AD dementia were censored and vice versa. P < .05 was 
considered to be significant.
3. Results
3.1. Demographics
Table 2 shows the baseline demographic features of the study population. Individuals with 
SCD in memory clinic cohorts were on average 10 years younger, and they were less often 
females, had more years of education, and were more often APOE ε4 positive than 
individuals with SCD in community-based cohorts and controls. Adjusted for random center 
effects, MMSE scores were lower in controls than in individuals with SCD. For all variables, 
individuals with SCD from the community were intermediate between SCD from a memory 
clinic and controls. Center characteristics are provided in Supplementary Table.
3.2. Progression to AD and non-AD dementia
During follow-up, 3.9 ± 2.2 years (range 0.9–12.8 years), 84 (6% of 1391) controls without 
SCD progressed to dementia, of which 61 (66% of demented) to AD and 23 (33% of 
demented) and non-AD. Among individuals with SCD, 194 (7% of 2978) progressed to 
dementia, attributed to AD for 127 (65% of demented) or another type of dementia for 67 
(35%). Within the non-AD dementia cohort, 30 (16% of all dementia cases) individuals with 
SCD progressed to VaD, 8 (4%) progressed to frontotemporal lobar degeneration (FTLD), 9 
(5%) to DLB, and 20 (10%) to another type of non-AD dementia. Fig. 2 shows the 
percentages of dementia diagnoses in community cohorts and memory clinics. In a 
multilevel model, we compared percentages of dementia diagnoses in community and 
memory clinic cohorts and found that individuals with SCD in community-based cohorts 
more often received a diagnosis of VaD (23% community vs. 9% memory clinic [P = .01]). 
By contrast, diagnoses of DLB and FTLD were more frequently made in a memory clinic 
setting (DLB 8% memory clinic vs. 1% community (P = .070); FTLD: 8% memory clinic 
versus 0% community, model did not converge). The percentage of a diagnosis of AD did 
not differ between recruitment settings (67% vs. 63%, P = .55), \ nor did the number of cases 
with “dementia other” (memory clinic 8% vs. community cohort 13% [P = .34]).
3.3. Incidence rate of dementia
Among individuals with SCD, the incidence rate of dementia was 17.7 (95% Poisson 
confidence interval 15.2–20.3) per 1000 person-years. The incidence rate per 1000 person-
years for dementia due to AD was 11.5 (9.6–13.7) and for non-AD dementia 6.1 (4.7–7.7). 
In controls without SCD, the incidence rate of dementia was 14.2 (11.3–17.6); 10.1 (7.7–
13.0) for AD and 4.1 (2.6–6.0) for non-AD. Table 3 shows the incidence rates of dementia in 
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memory clinics (20.0 [16.4–24.1]) and community cohorts (15.4 [12.3–19.0]) per decade 
and for AD and non-AD dementia separately. Incidence rates increased with age, as 
visualized in Figs. 3 and 4. Multivariate Cox proportional hazards models showed that 
compared to controls without SCD, individuals with SCD in memory clinic cohorts are at a 
clearly increased risk of dementia (Table 4). The increased risk of dementia in community-
based cohorts did not reach significance. In addition, higher age, lower MMSE, and APOE 
ε4 carrier status were independent predictors of incident dementia. We evaluated center 
random effects for MMSE and education in the Cox proportional hazards models, which did 
not specifically alter results, concluding that findings were generalizable for MMSE and 
education.
Stratified for AD or non-AD outcomes, the increased risk of dementia in individuals with 
SCD was particularly attributable to incident non-AD dementia. Lower MMSE increased the 
risk of both AD and non-AD dementia (Table 4), while higher age was associated with an 
increased risk of non-AD dementia. There was no significant effect of sex, education, or 
APOE in the stratified analyses.
4. Discussion
In this multicenter study including both memory clinic and community-based cohorts of 
SCD, we evaluated incidence rates of dementia, both for AD and non-AD. We found an 
overall dementia incidence rate in individuals with SCD of 17.7 per 1000 person-years, 
compared to 14.2 in controls without SCD. Particularly, in memory clinic patients with 
SCD, the risk of non-AD dementia is strongly increased. In line with incidence studies of 
dementia subtypes [19,20], roughly one of 3 incident dementia in individuals with SCD 
cases was due to non-AD. Of note, non-AD dementia in memory clinics often comprised 
FTD or DLB, while in community-based cohorts, VaD was relatively more common. Other 
determinants of incident dementia included higher age, lower baseline cognition, and APOE 
ε4 carriership.
Our data clearly showed that recruitment setting modifies the risk of progression from SCD 
to dementia. It is well known that recruitment setting (i.e. memory clinic vs. community) 
affects studies in SCD [3,21,22]. However, the number of studies directly comparing 
recruitment setting is small [9,23–25]. A previous meta-analysis suggested that the annual 
conversion rate from SCD to dementia did not differ between memory clinics and 
community cohorts [9], and likewise at first sight, our memory clinic cohorts also had only 
slightly higher incidence rates (20.1/1000 person-years) compared with community cohorts 
(15.4/1000 person-years). However, heterogeneity between studies has repeatedly been 
mentioned in SCD studies [9,21], and a recent study showed that progression to MCI is 
more common in individuals with SCD recruited at a memory clinic than in a community-
based setting [26]. We also observed great heterogeneity between cohorts in study design, 
center, and patient characteristics, and to allow meaningful pooling of data, we used a 
multilevel statistical approach, carefully taking into account center differences. Particularly, 
memory clinic cohorts were on average a decade younger, explaining their overall lower 
incidence. When we stratified by age, our data revealed that in every age bin, incidence of 
dementia is higher in the memory clinic than in the community-based cohorts of individuals 
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with SCD. The only exception was the oldest age bin >90 years, where data in memory 
clinics were simply lacking, and the incidence of dementia in community-based cohorts was 
high. Our data illustrate that memory clinic patients who actively seek help for their 
perceived cognitive problems, indeed, are more likely to experience the first (preclinical) 
signs of a neurodegenerative disease [23,24].
Our findings provide evidence that SCD is not only a potential harbinger of AD but also of 
other dementia. Two-third of incident dementia in individuals with SCD was attributable to 
AD dementia, whereas approximately one-third was attributable to another type of dementia. 
The relative frequencies of individuals with SCD progressing to FTLD, DLB, and VaD 
seemed comparable with previous dementia incidence studies [19,20,27–29]. In memory 
clinic cohorts, DLB and FTLD were more frequently diagnosed than in community cohorts. 
By contrast, VaD was more often diagnosed in the older community cohort individuals with 
SCD. This difference could be a reflection of differing operationalization of diagnostic 
criteria for dementia, which may be handled differently between settings [30], for example, 
VaD in memory clinic settings often requires neuroimaging criteria, whereas in community-
based settings such a diagnosis may be based on clinical presentation only. Diagnosis of 
DLB or FTLD requires careful neurological examination by an expert neurologist, available 
mostly in specialized clinics rather than in community settings. Also, individuals with early 
VaD or DLB might be referred for evaluation to general neurology, instead of a memory 
clinic, as patients complain rather of neurological symptoms, such as parkinsonism or gait 
change, than memory decline. Furthermore, individuals with FTLD may be less likely to 
participate in voluntary studies because of disease characteristics [31].
The large majority of individuals with SCD in both memory clinic and community-based 
cohorts did not progress to any type of dementia, but rather remained cognitively normal. 
Despite the growing interest in SCD as a putative first syndrome stage of AD, the group of 
individuals seeking help where a neurodegenerative disorder can be excluded as cause of 
their problems also merits our attention. From studies in the field of MCI and early studies 
in SCD, it is clear that, for example, cerebrospinal fluid biomarkers have particularly good 
negative predictive value, illustrating that their optimal clinical use is for reassurance of 
individuals with normal biomarkers [32,33]. Alternative causes of SCD could be subclinical 
psychiatric disorders, personality traits, or surmenage. Individuals with SCD who are 
unlikely to progress to AD or non-AD dementia could be reassured and might benefit from 
counseling and/or lifestyle interventions, aiming to promote a healthy brain.
We evaluated which determinants contributed to an increased risk of progression from SCD 
to dementia and found that higher age, lower baseline MMSE, APOE ε4 status, and 
recruitment setting resulted in an increased risk of dementia, which is consistent with the 
literature [9,34,35]. We found that higher age contributed relatively more to the risk of AD 
than non-AD dementia in individuals with SCD. A possible explanation could lie in the fact 
that some non-AD dementia, such as FTLD, are relatively more often diagnosed at a 
younger age, thus reflecting less contribution of a higher chronologic age in the risk of non-
AD dementia in comparison with AD dementia [31]. The effect of MMSE on the risk of 
clinical progression also seemed stronger for AD than for non-AD. The MMSE is mainly 
designed as a global cognitive screening tool and most sensitive for disturbances in memory 
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and orientation [18]. Because the memory domain is relatively less affected in non-AD 
dementia, it is conceivable that MMSE is less sensitive for non-AD dementia [36]. APOE ε4 
status was associated with an increased risk of dementia, which appeared to be attributable 
to the risk of AD but not to non-AD, which is in agreement with the literature [37,38].
The limitations of the study include the substantial heterogeneity in cohort characteristics. 
The heterogeneity includes differences in demographics of participants among centers and 
substantial inherent center characteristics such as the definition of SCD, the administered 
SCD questionnaires, the use of (magnetic resonance imaging, positron emission 
tomography, or cerebrospinal fluid) biomarkers in the diagnostic process, and the outcome 
measures (differences in dementia criteria used). Furthermore, recruitment setting has been 
shown to be a moderator of SCD results, as discussed previously. Nonetheless, we were able 
to combine these cohorts by using a multilevel statistical approach, using shared-frailty Cox 
models and taking into account random center effects. Our results underline the importance 
of the harmonized research criteria for SCD, which have been put forward by the SCD-I 
working group [3,39]. In this study, we had no information available on different domains of 
cognitive complaints, such as memory domains versus nonmemory domains. As one-third of 
dementia diagnoses were non-AD, evaluation of SCD in nonmemory domains using 
questionnaires and also qualitative assessment is of interest to better understand the 
underlying pathology of SCD [40]. Also, we had no comprehensive cognitive test battery or 
biomarker data available for a large part of our cohort, and we cannot exclude the possibility 
of misdiagnosis in a number of cases. Future studies should include a wider range of 
cognitive tests and biomarkers to further evaluate the process of differentiating between AD 
and non-AD types of dementia. We did not take into account all available SCD cohorts, but 
this collaborative study did originate from the International Society to Advance Alzheimer’s 
Research and Treatment’s SCD Professional Interest Area, including all centers that wanted 
to contribute data. The strengths of the study, therefore, include the large sample of SCD 
patients, with participating centers from around the world. Furthermore, this is the first time 
that the incidence of non-AD dementia is evaluated in the context of SCD.
Members of the international SCD Working Group (SCD-I) have published a conceptual 
framework on SCD research to facilitate harmonization of SCD research [3,39]. The 
framework, however, is focused on the detection of preclinical AD and not so much on the 
preclinical stages of other dementia. The risk of preclinical AD has been suggested to be 
specifically modified by self-reported memory decline [7], and a large overview of SCD 
measures indicated that most instruments indeed evaluate memory-specific decline [3,21]. 
However, as approximately one-third of progressing patients in our SCD sample progressed 
to another type of dementia than AD, the importance of nonmemory characteristics needs to 
be considered when evaluating SCD.
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RESEARCH IN CONTEXT
1. Systematic review: We evaluated literature on incidence numbers of 
subjective cognitive decline (SCD) and risk factors of progression from SCD 
to dementia, with a particular focus on both AD and non-AD types of 
dementia.
2. Interpretation: This large collaborative study including 2978 participants with 
SCD, indicated that SCD is a prodrome of both AD and non-AD dementia. 
Risk factors for progression from SCD to dementia included higher age, lower 
MMSE, apolipoprotein E, and recruitment setting, specifically memory clinic 
setting.
3. Future directions: As we evaluated risk factors for progression from SCD to 
dementia, we concluded that these risk factors, in particular recruitment 
setting, should be taken into account while interpreting and comparing future 
study results. Future studies may include biomarker data while assessing risk 
factors of progression from SCD to dementia.
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Fig. 1. 
Flowchart of participant selection. Overview of inclusion of participants. Abbreviations: 
MCI, mild cognitive impairment; SCD, subjective cognitive decline.
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Fig. 2. 
Type of dementia diagnosis in memory clinic and community settings. Dementia diagnoses 
per type of recruitment setting. Total number of dementia diagnoses: memory clinic n = 107, 
community n = 87. Results are represented as N (%).
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Fig. 3. 
Incidence rates of dementia and AD and non-AD dementia. (A) Incidence rates of dementia 
per decade in individuals with SCD and controls. (B) Incidence rates of AD and non-AD 
dementia per decade. Results are presented as incidence rates per 1000 person-years (95% 
Poisson confidence intervals) per decade. Abbreviations: AD, Alzheimer’s disease; CI, 
confidence interval; SCD, subjective cognitive decline.
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Fig. 4. 
Kaplan-Meier curves of cumulative risk of dementia in controls and individuals with 
subjective cognitive decline in memory clinic and community cohorts. Kaplan-Meier curves 
of the cumulative risk of progression to dementia per decade, stratified for recruitment 
setting.
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n 
1 
M
C 
vi
sit
 b
ec
au
se
 o
f 
co
m
pl
ai
nt
s
A
nn
ua
l F
U
75
52
23
G
er
m
an
 D
em
en
tia
 C
om
pe
te
nc
e 
N
et
w
o
rk
 (D
CN
) [
47
]
G
er
m
an
y
M
em
or
y 
cl
in
ic
; m
ul
tip
le
 
sin
gl
ec
en
te
r s
tu
di
es
N
or
m
al
 c
og
ni
tio
n 
1 
M
C 
vi
sit
 b
ec
au
se
 o
f 
co
m
pl
ai
nt
s P
ar
tic
ip
an
t d
id
 n
ot
 m
ee
t J
ak
- 
B
on
di
 c
rit
er
ia
 [4
8]
A
nn
ua
l F
U
25
6
25
6
0
D
ev
el
op
m
en
t o
f S
cr
ee
ni
ng
 
G
ui
de
lin
es
 a
nd
 C
lin
ic
al
 C
rit
er
ia
 
fo
r P
re
-d
em
en
tia
 A
D
 st
ud
y 
(D
ES
CR
IPA
) [
49
]
Eu
ro
pe
*
M
em
or
y 
cl
in
ic
; m
ul
tip
le
 
sin
gl
ec
en
te
r s
tu
di
es
N
or
m
al
 c
og
ni
tio
n 
1 
M
C 
vi
sit
 b
ec
au
se
 o
f 
co
m
pl
ai
nt
s
A
nn
ua
l F
U
24
5
22
4
0
H
el
le
ni
c 
Lo
ng
itu
di
na
l 
In
v
es
tig
at
io
n 
of
 A
gi
ng
 a
nd
 D
ie
t 
(H
EL
IA
D)
 [5
0]
G
re
ec
e
Co
m
m
un
ity
; s
in
gl
e-
ce
nt
er
N
or
m
al
 c
og
ni
tio
n 
1 
co
gn
iti
v
e 
co
m
pl
ai
nt
s 
qu
es
tio
nn
ai
re
: Y
es
A
nn
ua
l F
U
53
1
15
4
30
9
IN
SI
G
H
T 
pr
e-
A
D
 st
ud
y, 
Pa
ris
 
[5
1,
52
]
Fr
an
ce
Co
m
m
un
ity
; s
in
gl
e-
ce
nt
er
N
or
m
al
 c
og
ni
tio
n 
1 
co
gn
iti
v
e 
co
m
pl
ai
nt
s 
qu
es
tio
nn
ai
re
: Y
es
FU
 a
fte
r 3
 y
ea
rs
31
8
31
8
0
Le
ip
zi
g 
Lo
ng
itu
di
na
l S
tu
dy
 o
f t
he
 
A
ge
d 
(L
EI
LA
75
1) 
[53
]
G
er
m
an
y
Co
m
m
un
ity
; s
in
gl
e-
ce
nt
er
N
or
m
al
 c
og
ni
tio
n 
1 
co
gn
iti
v
e 
co
m
pl
ai
nt
s 
qu
es
tio
nn
ai
re
: Y
es
FU
 in
te
rv
al
 1
8 
m
on
th
s
67
0
16
9
50
1
Sy
dn
ey
 M
em
or
y 
an
d 
A
ge
in
g 
St
ud
y 
(M
AS
) [
54
]
A
us
tra
lia
Co
m
m
un
ity
; s
in
gl
e-
ce
nt
er
N
or
m
al
 c
og
ni
tio
n 
1 
co
gn
iti
v
e 
co
m
pl
ai
nt
s 
qu
es
tio
n:
 Y
es
FU
 in
te
rv
al
 2
4 
m
on
th
s
46
7
31
6
15
1
N
ew
 Y
o
rk
 U
ni
v
er
sit
y 
La
ng
on
e 
M
ed
ic
al
 C
en
te
r (
NY
U)
U
SA
M
em
or
y 
cl
in
ic
; s
in
gl
e-
ce
nt
er
N
or
m
al
 c
og
ni
tio
n 
1 
M
C 
vi
sit
 b
ec
au
se
 o
f 
co
m
pl
ai
nt
s
A
nn
ua
l F
U
48
8
40
9
0
A
bb
re
v
ia
tio
ns
: C
CI
, C
og
ni
tiv
e 
Ch
an
ge
 In
de
x
; F
U
, f
ol
lo
w
-u
p;
 M
C,
 m
em
or
y 
cl
in
ic
; S
CD
, s
ub
jec
tiv
e 
co
gn
iti
v
e 
de
cl
in
e.
N
OT
E:
 O
f t
he
 p
ar
tic
ip
at
in
g 
co
ho
rts
, t
he
re
 w
er
e 
ei
gh
t s
in
gl
e-
ce
nt
er
 st
ud
ie
s, 
tw
o
 m
u
lti
ce
nt
er
 st
ud
ie
s w
ith
 st
an
da
rd
iz
ed
 m
et
ho
ds
 (A
DN
I a
nd
 A
IB
L)
, a
nd
 tw
o
 c
o
ho
rts
 c
om
po
se
d 
of
 d
at
a 
fro
m
 m
ul
tip
le
 si
ng
le
-
ce
n
te
r s
tu
di
es
 (D
CN
 G
erm
an
y 
an
d 
D
ES
CR
IP
A
). A
DN
I a
nd
 th
e s
ing
le 
sit
e I
nd
ian
a A
DC
 co
ho
rt 
we
re 
co
mb
ine
d a
s b
oth
 w
ere
 as
ses
sed
 an
d i
nc
lud
ed
 ba
sed
 on
 th
e C
CI
.
*
To
 p
re
v
en
t p
os
sib
le
 o
v
er
la
p 
of
 p
ar
tic
ip
an
ts,
 a
ll 
ca
se
s f
ro
m
 th
e 
V
U
 M
ed
ic
al
 C
en
te
r i
nc
lu
de
d 
in
 th
e 
D
ES
CR
IP
A
 d
at
a 
se
t w
er
e 
no
t i
nc
lu
de
d 
in
 a
na
ly
se
s (
n =
 22
). S
ee
 Su
pp
lem
en
tar
y T
ab
le
 fo
r m
or
e 
in
fo
rm
at
io
n.
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Ta
bl
e 
2
B
as
el
in
e 
de
m
og
ra
ph
ic
 fe
at
ur
es
 o
f s
tu
dy
 p
ar
tic
ip
an
ts 
(N
 = 
43
69
)
A
ll
C
on
tr
o
ls
C
om
m
un
ity
M
em
or
y 
cl
in
ic
C
ha
ra
ct
er
ist
ic
s
N
 =
 4
36
9
N
 =
 1
39
1
N
 =
 1
44
8
N
 =
 1
53
0
P 
v
a
lu
e
N
um
be
r o
f c
oh
or
ts
6
5
6
A
ge
, y
ea
r
73
 ±
 9
77
 ±
 7
76
 ±
 6
67
 ±
 9
.
00
0
Fe
m
al
e 
ge
nd
er
26
11
 (6
0%
)
88
9 
(64
%)
90
1 
(62
%)
82
1 
(54
%)
.
00
0
M
M
SE
28
.3
 ±
 1
.7
27
.9
 ±
 1
.9
28
.4
 ±
 1
.4
28
.4
 ±
 1
.6
.
00
0*
Ed
uc
at
io
n,
 y
ea
r†
12
 ±
 4
11
 ±
 5
10
 ±
 4
14
 ±
 4
.
00
0
A
PO
E 
e4
 c
ar
rie
r‡
88
8 
(28
%)
18
4 
(26
%)
26
1 
(22
%)
44
3 
(36
%)
.
00
0
Fo
llo
w
-u
p,
 y
ea
r
3.
9 
± 
2.
2
4.
3 
± 
2.
0
3.
9 
± 
2.
0
3.
5 
± 
2.
3
.
00
0
N
OT
E:
 V
al
ue
s a
re
 d
isp
la
ye
d 
as
 u
na
dju
ste
d m
ean
 ± 
sta
nd
ard
 de
v
ia
tio
n 
(S
D)
 or
 N
 (%
). D
iff
er
en
ce
s b
et
w
ee
n 
m
em
or
y 
cl
in
ic
 a
nd
 c
om
m
un
ity
 c
oh
or
ts 
w
er
e 
as
se
ss
ed
 u
sin
g 
lin
ea
r m
ix
ed
 m
od
el
s (
co
nti
nu
ou
s 
v
ar
ia
bl
es
) o
r g
en
era
liz
ed
 es
tim
ati
ng
 eq
ua
tio
ns
 (d
ich
oto
mo
us
 va
ria
bl
es
) t
ak
ing
 in
to 
ac
co
un
t c
en
ter
 ra
nd
om
 ef
fe
ct
s.
*
W
he
n 
ta
ki
ng
 in
to
 a
cc
ou
nt
 c
en
te
r r
an
do
m
 e
ffe
ct
s, 
M
M
SE
 is
 lo
w
er
 in
 c
on
tro
ls 
ve
rs
u
s 
co
m
m
u
n
ity
 c
oh
or
ts 
ve
rs
u
s 
m
em
o
ry
 c
lin
ic
 c
oh
or
ts 
(P
 < 
.00
1),
 w
he
rea
s u
na
dju
ste
d m
ean
s a
re 
sho
w
n
 in
 th
e 
ta
bl
e.
† D
at
a 
av
ai
la
bl
e 
fo
r 7
7%
 (m
em
ory
 cl
ini
c 9
8%
, c
om
mu
nit
y 4
4%
, c
on
tro
ls 
88
%)
.
‡ D
at
a 
av
ai
la
bl
e 
fo
r 7
2%
 (a
v
ai
la
bi
lit
y 
m
em
or
y 
cl
in
ic
 8
2%
, c
om
m
un
ity
 8
1%
, c
on
tro
ls 
51
%
).
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Ta
bl
e 
3
In
ci
de
nc
e 
ra
te
s o
f d
em
en
tia
 in
 g
en
er
al
, a
nd
 d
em
en
tia
 d
ue
 to
 A
D
 a
nd
 n
on
-A
D
N
um
be
r o
f p
er
so
n 
ye
a
rs
In
ci
de
nc
e 
ra
te
/1
00
0 
pe
rs
on
-y
ea
rs
 (9
5%
 Po
iss
on
 c
on
fid
en
ce
 in
te
rv
a
ls)
G
ro
u
ps
 w
ith
 a
ge
-b
in
s
D
em
en
tia
A
D
N
on
-A
D
Co
nt
ro
ls 
(n 
= 1
39
1)
 
A
ll
14
.2
 (1
1.3
–1
7.6
)
10
.1
 (7
.7–
13
.0)
4.
1 
(2.
6–
6.0
)
 
A
ge
 c
at
eg
or
y
 
<
60
55
0
0
0
 
60
–7
0
85
9
2 
(0–
8)
2 
(0–
8)
0
 
70
–8
0
33
79
7(5
–1
1)
4 
(2–
7)
3 
(2–
6)
 
80
–9
0
15
47
33
 (2
5–
43
)
25
 (1
8–
34
)
8 
(4–
14
)
 
>
90
81
74
 (2
7–
16
1)
62
 (2
0–
14
4)
12
 (0
–6
9)
Co
m
m
un
ity
 (n
 = 
14
48
)
 
A
ll
56
47
15
.4
 (1
2.3
–1
9.0
)
9.
7 
(7.
3–
12
.7)
5.
7 
(3.
9–
8.0
)
 
A
ge
 c
at
eg
or
y
 
<
60
12
0
0
0
 
60
–7
0
90
4
2 
(0–
8)
2 
(0–
8)
0
 
70
–8
0
32
22
11
 (8
–1
5)
6 
(4–
9)
5 
(3–
8)
 
80
–9
0
15
09
32
 (2
4–
42
)
23
 (1
6–
32
)
9 
(5–
16
)
 
>
90
47
60
(12
–1
75
)
20
(1–
11
1)
40
 (5
–1
45
)
M
em
or
y 
cl
in
ic
 (n
 = 
15
30
)
 
A
ll
53
55
20
.1
 (1
6.4
–2
4.1
)
13
.4
(10
.5–
16
.9)
6.
5 
(4.
6–
9.1
)
 
A
ge
 c
at
eg
or
y
 
<
60
12
71
6 
(2–
11
)
2 
(0–
6)
4 
(1–
9)
 
60
–7
0
19
52
17
 (1
2–
24
)
11
 (7
–1
6)
6 
(3–
11
)
 
70
–8
0
15
71
32
 (2
4–
42
)
22
 (1
5–
30
)
10
 (6
–1
6)
 
80
–9
0
44
7
26
 (2
0–
58
)
31
 (1
7–
52
)
4(1
–1
5)
 
>
90
12
0
0
0
A
bb
re
v
ia
tio
n:
 A
D
, A
lz
he
im
er
’s
 d
ise
as
e.
N
OT
E:
 R
es
ul
ts 
ar
e 
di
sp
la
ye
d 
as
 in
ci
de
nc
e 
ra
te
s (
95
% 
Po
iss
on
 co
nfi
de
nc
e 
in
te
rv
al
) p
er 
10
00
 pe
rso
n-y
ea
rs.
 A
na
lys
es 
str
ati
fie
d 
fo
r A
D
 a
nd
 n
on
-A
D
 ty
pe
s o
f d
em
en
tia
, a
ge
 c
at
eg
or
y,
 
an
d 
re
cr
ui
tm
en
t s
et
tin
g.
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tio
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 b
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de
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in
an
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an
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th
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en
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en
er
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 d
em
en
tia
 d
ue
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D
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nd
 n
on
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D
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 c
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SC
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 sa
m
pl
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36
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en
tia
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D
N
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-A
D
D
et
er
m
in
an
t
M
od
el
 1
M
od
el
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M
od
el
 1
M
od
el
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M
od
el
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M
od
el
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Co
nt
ro
ls
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f
re
f
re
f
re
f
re
f
re
f
SC
D
—
co
m
m
un
ity
2.
1 
(0.
6–
7.7
)
1.
5 
(0.
4–
5.8
)
1.
8 
(0.
8–
4.1
)
0.
7 
(0.
3–
1.9
)
4.
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(1.
1–
19
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(0.
5–
9.7
)
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m
em
or
y 
cl
in
ic
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.9–
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.4
 (3
.4–
32
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(0.
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3.6
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4.1
)
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.7
 (3
.1–
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.4)
7.
1 
(1.
8–
27
.3)
A
ge
, y
ea
rs
1.
1 
(1.
1–
1.1
)
1.
1 
(1.
1–
1.1
)
1.
0 
(1.
0–
1.0
)
1.
0 
(1.
0–
1.0
)
1.
09
 (1
.05
–1
.12
)
1.
07
 (1
.02
–1
.11
)
Fe
m
al
e 
ge
nd
er
1.
1 
(0.
9–
1.4
)
1.
0 
(0.
7–
1.5
)
1.
0 
(0.
9–
1.0
4)
1.
0 
(0.
9–
1.1
)
0.
8 
(0.
5–
1.3
)
0.
6 
(0.
3–
1.0
)
M
M
SE
h
0.
7 
(0.
65
–0
.8)
0.
95
 (0
.92
–0
.98
)
0.
8 
(0.
7–
0.9
)
Ed
uc
at
io
n,
 y
ea
rs
*
1.
0 
(0.
97
–1
.1)
1.
0 
(0.
98
–1
.01
)
1.
0 
(0.
9–
1.1
)
A
PO
E 
ε4
 st
at
us
†
1.
8 
(1.
3–
2.5
)
1.
0 
(0.
9–
1.1
)
1.
1 
(0.
6–
2.1
)
A
bb
re
v
ia
tio
ns
: A
D
, A
lz
he
im
er
’s
 d
ise
as
e;
 S
CD
, s
ub
jec
tiv
e 
co
gn
iti
v
e 
de
cl
in
e.
N
OT
E:
 R
es
ul
ts 
ar
e 
pr
es
en
te
d 
as
 h
az
ar
d 
ra
tio
s (
95
% 
co
nfi
de
nc
e 
in
te
rv
al
) a
nd
 re
fle
ct 
the
 ri
sk
 of
 pr
og
res
sio
n f
rom
 SC
D 
to 
de
me
nti
a i
n g
en
era
l a
nd
 de
me
nti
a d
ue
 to
 A
D 
an
d n
on
-A
D.
 M
od
el 
1: 
ag
e a
nd
 ge
nd
er 
ad
jus
ted
. M
od
el 
2; 
ad
dit
ion
all
y a
dju
ste
d f
or 
MM
SE
, e
du
cat
ion
 in
 ye
ars
, a
nd
 A
PO
E 
ε4
 st
at
us
 (d
ue
 to
 m
iss
ing
 da
ta 
in 
M
M
SE
, e
du
ca
tio
n, 
an
d A
PO
E,
 m
od
el 
2 h
as 
les
s o
bs
erv
at
io
ns
). H
Rs
 w
ere
 ca
lcu
lat
ed
 pe
r 
de
te
rm
in
an
t i
n 
un
iv
ar
ia
te
 m
od
el
s a
nd
 c
om
bi
ne
d 
in
 m
ul
tiv
ar
ia
te
 m
od
el
s.
h H
ig
he
r s
co
re
s r
ef
le
ct
 b
et
te
r p
er
fo
rm
an
ce
.
*
D
at
a 
av
ai
la
bl
e 
fo
r 7
7%
.
† D
at
a 
av
ai
la
bl
e 
fo
r 7
2%
.
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